Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.86% | 31.05% | -7.51% | 4.34% | -153.14% |
| Total Depreciation and Amortization | 205.94% | -91.59% | -2.67% | 96.50% | -6.96% |
| Total Amortization of Deferred Charges | -25.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -43.17% | 37.02% | 12.74% | -83.29% | 356.63% |
| Change in Net Operating Assets | 335.16% | 33.48% | -1,504.38% | -100.90% | 199.08% |
| Cash from Operations | 60.45% | 40.77% | -21.52% | -213.88% | 171.91% |
| Capital Expenditure | -- | 100.00% | -540.00% | 98.20% | -143.86% |
| Sale of Property, Plant, and Equipment | -99.56% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -99.56% | 1,509.38% | -540.00% | 98.20% | -143.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -99.76% | 80.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -99.76% | 80.00% |
| Foreign Exchange rate Adjustments | 122.78% | -134.32% | 73.35% | 141.98% | -218.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.44% | 5.35% | -8.24% | -287.69% | 153.96% |